Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:

NCT ID: NCT05782283 Recruiting - Cirrhosis Clinical Trials

A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram

ADVANCE
Start date: April 18, 2023
Phase: N/A
Study type: Interventional

The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.

NCT ID: NCT05769868 Recruiting - Diabetes Mellitus Clinical Trials

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

CIBERbBECHO
Start date: April 18, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.

NCT ID: NCT05744713 Not yet recruiting - Cirrhosis Clinical Trials

An Observational Study of Patients With Chronic Liver Disease

Start date: May 1, 2023
Phase:
Study type: Observational

TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

NCT ID: NCT05740358 Recruiting - Cirrhosis Clinical Trials

Liver Cirrhosis Network Cohort Study

LCN-C
Start date: November 14, 2022
Phase:
Study type: Observational

Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

NCT ID: NCT05737030 Recruiting - Cirrhosis Clinical Trials

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

LOLAbiome
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

NCT ID: NCT05726032 Recruiting - Cirrhosis Clinical Trials

Empagliflozin in Patients With Cirrhosis and Ascites

EMPA Liver
Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

NCT ID: NCT05724485 Completed - Quality of Life Clinical Trials

Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this randomized controlled trial is to compare the efficacy and safety of branched-chain amino acids (BCAA) versus placebo for treating muscle cramps in cirrhotic patients. The main questions it aims to answer are: - Compared the effect of BCAA versus placebo on muscle cramp frequency in cirrhotic patients - Compared the effect of BCAA versus placebo on muscle cramp duration and severity in cirrhotic patients - Compared the effect of BCAA versus placebo on quality of life in cirrhotic patients with muscle cramps Participants with cirrhosis who have experienced muscle cramps at least once per week will be randomized to receive either a placebo or 12.45 grams of BCAA orally per day for 12 weeks.

NCT ID: NCT05689268 Completed - Cirrhosis Clinical Trials

EUS-PPG vs HVPG in Portal Hypertension

GRAPE
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the correlation of the calculated portal pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with a conventional 22 G needle guided by EUS and indirect portal vein pressure measurements using the interventional radiology based hepatic venous pressure gradient (HVPG) procedure.

NCT ID: NCT05635266 Recruiting - Stroke Clinical Trials

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Start date: October 26, 2021
Phase:
Study type: Observational

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

NCT ID: NCT05548452 Recruiting - Clinical trials for Alcohol Use Disorder

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

IMPACT
Start date: November 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.